U.S. Arthritis Market Trends Analysis, Top Manufacturers, Shares, Growth Opportunities, Statistics and Forecast by 2029

The major factor that is expected to drive the growth of the U.S. arthritis market is rising patient awareness of arthritis treatment, which leads to increased adoption of diagnosis and treatment. The sedentary lifestyle tradition leading to reduced indulgence in physical activities is also a major factor. There is a substantial rise in obesity and unhealthy food habits which is expected to increase the demand for Arthritis drugs.

Moreover, the geriatric population is most susceptible to arthritis, which is expected to boost the growth of the market. However, the high cost associated with medication and therapy is expected to hamper the growth of the market.

Various government initiatives to aid awareness and correct diagnosis of arthritis may boost the growth of the market.

The U.S. arthritis market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.2% in the forecast period of 2022 to 2029 and is expected to reach USD 78,400.47 million by 2029 from USD 36,046.73 million in 2021.

Get Full Access of Report @
https://www.databridgemarketresearch.com/reports/us-arthritis-market

Competitive Landscape and U.S. Arthritis Market Share Analysis

The U.S. arthritis market competitive landscape provides details about the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the U.S. arthritis market.

Some of the major players operating in the U.S. arthritis market are AbbVie Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Amgen Inc., F. Hoffman-La Roche Ltd, Novartis AG, Pfizer Inc., UCB S.A., Sanofi, Flexion Therapeutics Inc., Celltrion Healthcare Co., Ltd., Swedish Orphan Biovitrum AB, Bio-Rad Laboratories, Inc., Anika Therapeutics, Inc., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Abbott, Apotex Inc., Samsung Bioepis (A Subsidiary of Samsung Biologics), Beckman Coulter Inc., among others.

Browse More Reports :

https://marketresearchlink.blogspot.com/2023/05/asia-pacific-wine-market-in-depth.html
https://marketresearchlink.blogspot.com/2023/05/north-america-bone-glue-market-to-see.html
https://marketresearchlink.blogspot.com/2023/05/cannabi-seeds-market-trends-share.html
https://marketresearchlink.blogspot.com/2023/05/europe-hearing-aid-market-size-advanced.html
https://marketresearchlink.blogspot.com/2023/05/north-america-cardiac-monitoring-and.html

Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.